Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30874306 | 1.00 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3KDM4ECYP2D6 | |
| SCHEMBL29870462 | 1.00 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3KDM4ECYP2D6 | |
| SCHEMBL20721725 | 1.00 | SLC6A4 (0.48) | SLC6A4SLC6A2SLC6A3KDM4ECYP2D6 | |
| SCHEMBL9012682 | 0.78 | TSHR (0.46) | KDM4ETSHR | |
| SCHEMBL7339250 | 0.78 | TSHR (0.46) | KDM4ETSHR | |
| SCHEMBL982856 | 0.78 | TSHR (0.46) | KDM4ETSHR | |
| SCHEMBL7259690 | 0.76 | MEN1 (0.44) | KDM4E | |
| SCHEMBL28730834 | 0.76 | MEN1 (0.44) | KDM4E | |
| SCHEMBL3152410 | 0.75 | CYP2A6 (0.38) | SLC6A4SLC6A2SLC6A3DRD2KCNH2 | |
| SCHEMBL9099294 | 0.75 | SLC6A2 (0.41) | SLC6A4SLC6A2SLC6A3CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117866177-A | Biodegradable full polyester nano particle and preparation method and application thereof | 复旦大学 | 2024-04-12 | — | — | CN | claimed |
| WO-2006052985-A1 | LACTONES AS NEW OXYGENATE FUEL ADDITIVES, FUELS BASED THEREON AND METHODS FOR USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-05-18 | — | — | WO | claimed |
| US-20060096158-A1 | Lactones as new oxygenate fuel additives, fuels based thereon and methods for using same | ROBINSON J M | 2006-05-11 | — | — | US | claimed |
| US-6797745-B1 | Hot melt inks containing styrene or terpene polymers | XEROX CORPORATION | 2004-09-28 | — | — | US | claimed |
| US-6461417-B1 | Ink compositions | XEROX CORPORATION | 2002-10-08 | — | — | US | claimed |
| US-6117223-A | Hot melt inks containing polyketones | XEROX CORPORATION (US) | 2000-09-12 | — | — | US | claimed |
| CN-117866177-A | Biodegradable full polyester nano particle and preparation method and application thereof | 复旦大学 | 2024-04-12 | — | — | CN | disclosed |
| US-7196196-B2 | Substituted imidazo[1, 2-a]-5,6,7,8-tetrahydropyridine-8-ones, method for their production and the use thereof for producing imidazo[1,2-a]pyridines | BASF AKTIENGESELLSCHAFT (DE) | 2007-03-27 | — | — | US | disclosed |
| WO-2006052985-A1 | LACTONES AS NEW OXYGENATE FUEL ADDITIVES, FUELS BASED THEREON AND METHODS FOR USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060096158-A1 | Lactones as new oxygenate fuel additives, fuels based thereon and methods for using same | ROBINSON J M | 2006-05-11 | — | — | US | disclosed |
| US-20050020620-A1 | Substituted imidazo[1, 2-a]-5,6,7,8-tetrahydropyridine-8-ones, method for their production and the use thereof for producing imidazo[1,2-a]pyridines | BASF AKTIENGESELLSCHAFT (DE) | 2005-01-27 | — | — | US | disclosed |
| US-6797745-B1 | Hot melt inks containing styrene or terpene polymers | XEROX CORPORATION | 2004-09-28 | — | — | US | disclosed |
| US-6461417-B1 | Ink compositions | XEROX CORPORATION | 2002-10-08 | — | — | US | disclosed |
| US-6117223-A | Hot melt inks containing polyketones | XEROX CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020620-A1 | Substituted imidazo[1, 2-a]-5,6,7,8-tetrahydropyridine-8-ones, method for their production and the use thereof for producing imidazo[1,2-a]pyridines | BTN3A1, DHPS, NISCH | SLC6A4 4537/4885SLC6A2 4670/4885SLC6A3 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.